Micrazym (Pancreatin)

Pancreatin contains a blend of lipase, amylase, and protease enzymes that replicate the natural activity of the pancreas. After oral ingestion, the enzymes are protected from stomach acid and released in the small intestine where they catalyze the hydrolysis of dietary fats, carbohydrates, and proteins into smaller molecules that can be readily absorbed, compensating for the body's own enzyme shortfall.

The appropriate dose of Micrazym is individualized and determined by the prescribing healthcare professional based on the patient’s age, weight, severity of enzyme deficiency, and dietary fat intake. Dosage adjustments are made according to clinical response and tolerance, and patients should follow the specific instructions provided by their prescriber.

Safety data for Micrazym in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case carefully and discuss any concerns with the patient before initiating therapy.

To request Micrazym, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assist with import documentation.

Micrazym contains pancreatin derived from porcine pancreas, similar to many other pancreatic enzyme preparations. Differences among products generally relate to enzyme activity units, formulation (enteric‑coated tablets, capsules, or powders), and excipients. Clinicians may choose Micrazym based on its specific activity profile, patient tolerance, and availability through GNH India’s global supply network.

Micrazym should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed. Do not store in a refrigerator or freezer unless the manufacturer’s label explicitly states otherwise.

Micrazym is taken orally, usually with each main meal and snack that contains fat. The tablets or capsules should be swallowed whole with a sufficient amount of water. Dosing may be adjusted based on the size of the meal and the patient’s clinical response, following the prescriber’s guidance.

The most serious adverse events associated with Micrazym include allergic reactions such as rash, itching, swelling, or anaphylaxis, severe abdominal pain that could signal pancreatitis exacerbation, and rare cases of intestinal obstruction. Patients should seek immediate medical attention if they experience any of these symptoms.

Micrazym should be avoided in individuals with a known hypersensitivity to pancreatin or any porcine‑derived products. Patients with severe active gastrointestinal disease where enzyme therapy is contraindicated should also refrain from use. As always, a healthcare professional should assess suitability before initiating therapy.